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Pulmonary ﬁbrosis is a progressive, disabling disease with mortality rates that appear to be increasing in the western population,
including the USA. There are over 140 known causes of pulmonary ﬁbrosis as well as many unknown causes. Treatment options
for this disease are limited due to poor understanding of the molecular mechanisms of the disease progression. However,
recent progress in inﬂammasome research has greatly contributed to our understanding of its role in inﬂammation and ﬁbrosis
development. The inﬂammasome is a multiprotein complex that is an important component of both the innate and adaptive
immune systems. Activation of proinﬂammatory cytokines following inﬂammasome assembly, such as IL-1β and IL-18, has been
associated with development of PF. In addition, components of the inﬂammasome complex itself, such as the adaptor protein
ASC have been associated with PF development. Recent evidence suggesting that the ﬁbrotic process can be reversed via blockade
of pathways associated with inﬂammasome activity may provide hope for future drug strategies. In this paper we will give an
introduction to pulmonary ﬁbrosis and its known causes. In addition, we will discuss the importance of the inﬂammasome in the
development of pulmonary ﬁbrosis as well as discuss potential future treatment options.
1.Introduction
Five million people worldwide are aﬀected by pulmonary
ﬁbrosis (PF). According to the Pulmonary Fibrosis Founda-
tion and Centre for Clinical Epidemiology and Biostatistics,
there is an estimated 200,000 patients with PF of which
more than 40,000 die each year in the USA alone [1].
The symptoms of PF are obscure and mimic other clinical
pathologies such as chronic obstructive pulmonary disease,
heart failure, and aging, thus misdiagnosis can occur. As a
consequence,theactualnumberofpeopleaﬀectedbyPFmay
besigniﬁcantlyhigherthanthereportedﬁgure.Furthermore,
varying terminology and lack of standard diagnostic criteria
have complicated collection of accurate data.
The average age at the time of diagnosis of PF is 60–
65 years. However, in the USA mortality rates in younger
populations are increasing. In recent years, the rate of
diagnosisforPFhascontinuedtoriseintheolderpopulation
and evidence suggests that mortality rates for both men and
women with PF will continue to rise for the foreseeable
future [2]. Many people with the disease live only three to
ﬁve years after diagnosis, as there is no eﬀectivetreatmentfor
PF.
Most cases of PF are idiopathic in nature with unknown
events initiating the onset of the disease, although various
risk factors have been identiﬁed. Importantly, PF is not a
guaranteed outcome for every individual who is potentially
at high risk—suggesting a multifactorial mechanism is
involved in development of PF. One hypothesis suggests
that key events in the development of PF include an acute
inﬂammatory response following exposure to an injurious
agent followed by abnormal tissue repair and disruption of
the lung architecture [3]. Alternatively, it has been suggested
that the idiopathic form of PF is largely an epithelial-
dependent ﬁbrotic process that functions independently of
any inﬂammatory pathways [4]. This theory, along with a
lack of eﬃcacy for anti-inﬂammatory/immunosuppressive
therapies in PF patients, has lead to a reevaluation of the role
of inﬂammation in the development of PF [5]. Additionally,
evidence in mice suggesting that ﬁbrosis can develop with a
minimal amount of inﬂammation has further complicated
the issue [6]. Nevertheless, there is a large body of evidence2 Pulmonary Medicine
implicating inﬂammatory pathways in the overall etiology
of PF [7–9]. It is likely that studies exploring more speciﬁc
arms of the immune system, such as regulation of the
inﬂammasome, will shed new light on its role in the early
development of PF.
In contrast to the idiopathic form of PF, there are
many known causes such as exposure to respirable par-
ticles and toxicants, viral infections, oxidative stress, and
gastroesophageal reﬂux disease that have been shown to
initiate an inﬂammatory response and may induce events
associated with PF [10]. Once respired particles and/or
pathogens arrive inside the alveoli, they are engulfed by
alveolar macrophages, which play an important role in the
recognition,uptake,andclearanceofparticlesfromthelungs
[11]. Normally, uptake of the particle by the macrophage
results in phagosome formation. The phagosome can then
fuse with the lysosome-releasing lysosomal enzymes and
ultimately destroying the foreign matter [12, 13]. However,
in some cases, engulﬁng particles such as silica or asbestos
causeslysosomalmembranepermeabilizationandtherelease
of cathepsins into the cytosol where they contribute to
apoptosis signaling [14] and inﬂammasome activation [15,
16]. At this stage, apoptosis results in incompletely digested
particles remaining inside the lung for extended periods of
time [17]. Unsuccessful clearance of these particles cause
repetitive inﬂammation due to prolonged interaction with
both immune and nonimmune cell populations. Further-
more, the release of cathepsin B activates the inﬂammasome
[18].
In addition to environmental exposures, approximately
3% of PF cases are due to adverse side eﬀects of many
prescribed drugs [19]. In fact, there are nearly three hundred
drugs that have been associated with ﬁbrotic lung diseases, a
topicthatisthoroughlyreviewedbyCamusetal.[20].Unfor-
tunately,mostcasesofdrug-inducedPFoccurduringnormal
dosing regimens in a small percentage of susceptible individ-
uals, making early detection and prevention diﬃcult [20].
Drugs most commonly associated with irreversible cases
of PF include amiodarone, bleomycin, nonsteroidal anti-
inﬂammatory drugs (NSAID), most alkylating agents [20],
and methotrexate [21, 22]. Mechanisms of drug-induced
PF are mostly unknown; however, evidence suggests that
the inﬂammasome may play a role. For example, bleomycin
has been used to induce PF in murine models in order to
better understand molecular mechanisms [23]. It has been
demonstrated that bleomycin-induced lung inﬂammation
and remodeling is largely mediated by uric acid, which is
released from dying cells, upon injury or insult [24]. When
uric acid is released from dying cells activation of the NALP3
inﬂammasome occurs, which results in enhanced IL-1β
production and subsequent inﬂammation [24]. In addition,
it is believed that bleomycin induces PF pathology through
the IL-1R1/MyD88 signaling pathway [25]. Furthermore,
a role for the NALP3 inﬂammasome in acetominophen-
induced hepatotoxicity was recently reported and may shed
light on the mechanisms of NSAID-induced PF [26]. Lastly,
as a folic acid analog, methotrexate is one of the oldest
and most eﬃcacious antineoplastic drugs. However, some
studies have suggested that a link between the use of
methotrexate and development of PF exists [21, 22]. It
is likely that the mechanism of methotrexate-induced PF
involves modulation of an endogenous anti-inﬂammatory
agent known as adenosine, which has been reported to
have proﬁbrotic eﬀects in some experimental models [27]
andreportedlyactivatestheNALP3inﬂammasomefollowing
release from necrotic cells [28].
In addition to complications caused by drug-induced PF,
littleprogresshasbeenmadetowardtreatmentofthedisease.
Atthistime,thereisnopharmacologicaltreatmentknownto
restore normal lung tissue architecture, which is paramount
to regaining normal lung function [29]. The treatment
choices for PF are limited and are aimed at preventing
more lung scarring, relieving symptoms and improving
the quality of life [30]. Conventional treatment options
for PF include antitussives, bronchodilators, corticosteroids,
immunosuppressive/cytotoxic agents, and antiﬁbrotic agents
[31–33] (see Figure 1). Drugs used to suppress the immune
response have been used as a method for treating PF, but like
other current therapies, these drugs have had little success
in altering the normal course of PF disease progression [31,
34]. However, recent ﬁndings on the role of inﬂammatory
pathways and the cytokines involved in those pathways may
provide future direction for the development of new drugs
for the treatment of PF. Traditionally, onset and progression
of PF has been considered an irreversible and progressive
disease. However, there is evidence to suggest that under
certain conditions, the ﬁbrotic process can be reversed—
which has broad implications for PF patients.
Results in our lab demonstrate that collagen deposi-
tion, a key step in the ﬁbrotic process, is reversible once
exposure to asymmetric dimethylarginine has been removed
[35]. In addition, the use of an interleukin-1 receptor
(IL-1R) antagonist was able to both prevent and reverse
bleomycin-induced pulmonary ﬁbrosis in mice [36]. This
suggests that drugs designed against components of the
inﬂammasome may also have potential for future treatment
regimens. The inﬂammasome is an important regulator of
the proinﬂammatory cytokines, interleukin-1 beta (IL-1β),
and interleukin-18 (IL-18). Both IL-1β and IL-18 have been
linked to PF development and pathogenesis while clinical
and experimental studies point to a crucial role of IL-1β
and IL-18 in acute and chronic inﬂammation [37]. Another
evidence supporting the potential for the reversal of PF
pathology has been demonstrated through studies on IL-13,
an inﬂammatory cytokine known to be involved in ﬁbrosis
[38–40]. This has signiﬁcant implications for PF patients as
it provides hope for future treatment strategies focusing on
inﬂammasome activity.
2.CausalFactorsinPF DiseaseDevelopment
2.1. Environmental Exposures. While a high percentage of PF
cases are idiopathic in nature, PF is also associated with envi-
ronmental or occupational exposures to respirable asbestos
particles, silica, and metal dust. Other common factors that
can contribute to PF include a genetic predisposition, some
medications, and medical conditions. In addition, exposurePulmonary Medicine 3
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Figure 1: Present treatment options for PF. Available treatment options for PF include antitussives and bronchodilators, which relieve
symptomsofdryunproductivecoughandbronchospasm,respectively.Inaddition,corticosteroidsareoftenadministeredforsustainedrelief
of bronchospasm. Immunosuppressive/cytotoxic agents are usually reserved for patients not responding to steroid treatment or suﬀering
f r o ma d v e r s es i d ee ﬀects. Lung transfer surgery is only considered in patients less than 65 years of age and can lead to fatal complications.
Oxygen supplementation has positive outcomes on patient health. However, the personal inconvenience may aﬀect patient compliance.
toviralinfectionssuchasinﬂuenza Avirus,hepatitis Cvirus,
HIV-Avirus,andherpesvirus-6canalsoincreasetheriskfor
PF [10].
2.2. Genetics. PF has a complicated etiology that most likely
contains a genetic component that is strongly inﬂuenced by
environmental exposures. Several polymorphisms have been
associated with the development of PF. In addition, patients
with accelerated clinical progression have diﬀerent genetic
proﬁles than less severe case studies [41].
Cases of familial PF follow an autosomal dominant
pattern [42] while the pathological symptoms remain indis-
tinguishable from nonfamilial cases with the exception of the
age of onset [43]. However, variable penetrance, even within
genetically susceptible individuals and families, suggests that
PF disease outcome is highly inﬂuenced by environmental
factors [42].
3. Inﬂammasome Activity
3.1. What Is the Inﬂammasome? The inﬂammasome is an
important component of both the innate and adaptive
immune systems [44]. The innate immune system provides
immediate defense against infections and triggers the T and
B cells of the adaptive immune system. Initial studies have
identiﬁed the NALP (NACHT domain-, leucine-rich repeat
and pyrin domain-containing protein) family of proteins
as a critical component of the inﬂammasome [45]. The
NALP family of proteins plays a crucial role in alerting the
mammalian immune system to the presence of “danger”
conditions and pathogens [46].
NALP is a member of the NOD-like receptor (NLR)
family. Other family members of NLR are NAIP (NLR
family, apoptosis inhibitory protein) and NLRC4 (NLR
family, CARD domain containing 4). The NLR family
members all have similar structures, with a ligand binding
leucine-rich repeat domain at the carboxy terminus and
an intermediary NACHT domain for nucleotide binding
and self-oligomerization [47]. NLR family members also
contain an eﬀector domain at the amino terminus consisting
of either a pyrin domain (PYD), a caspase activation and
recruitment domain (CARD), or a baculovirus inhibitor of
apoptosis protein repeat (BIR) [48]. It is thought that the
main function of the NLR is the regulation of proinﬂam-
matory cytokines such as IL-1β and IL-18. Though diverse
molecularentitiesincludingbacteria,viruses,componentsof
dying cells, immune activators, and crystalline or aggregated
materials can activate NLR protein (NLRP), the precise
mechanism of how NLRs recognize their ligands is unclear.
Out of the several NALP proteins, the NALP3, or cryopy-
rin, inﬂammasome has been the most extensively studied.
Though signals and mechanisms leading to inﬂammasome
activation are still poorly understood, it has been reported
that NALP3 activation is required for stimulating inﬂam-
masome assembly [48]. Once assembled, the inﬂammasome
activates caspase-1, which catalyzes cleavage of the inactive
precursor molecules pro-IL-1β and pro-IL-18 to their active
forms, IL-1β and IL-18 [49]. IL-1β and IL-18 can only be
secreted out of the cell in their active form [50]. Though
caspase-1 is important for cleavage of pro-IL-1β and proIL-
18, there is evidence that these proinﬂammatory cytokines
can be cleaved by a non-caspase-1 mechanism as well. For
example, proteinase-3 has also been reported to cleave pro-
IL-1β and pro-IL-18 to generate mature forms of these
cytokines in the absence of caspase-1 [50]. This may help
explain the wide variety of signals that are known to activate
the inﬂammasome.
In addition to NALP, the adaptor protein ASC (apop-
tosis-associated speck-like protein containing a caspase
recruitmentdomain(CARD))isanimportantcomponentof
the inﬂammasome complex. Adaptor protein ASC connects
NALP proteins to pro-caspase-1 leading to cleavage of the
CARD domain of pro-caspase-1 [46]. It has been reported
by several research groups that, in the absence of NALP3 or
ASC in genetically deﬁcient mice, there is no activation or
maturation of IL-1β [24, 51–54]. In fact, the ASC protein
is required for bleomycin-induced IL-1β production and4 Pulmonary Medicine
inﬂammation [25]. Therefore, NALP3 and ASC are potential
therapeutic targets for treating chronic inﬂammation and
ﬁbrosis.
The exact composition of an inﬂammasome complex
depends on the activator, which initiates inﬂammasome
assembly. For example, NALP-1 can directly bind and
activate caspase-1 and/or caspase-5 via its unique CARD
domain without the help of the adaptor protein (ASC) [55].
Once the inﬂammasome complex has been assembled, the
downstream signaling due to activation of proinﬂammatory
cytokines can contribute to the progression of many inﬂam-
matory diseases, including PF.
3.2. Inﬂammasome Activity and Fibrosis. Molecular mecha-
nisms of acute lung injury resulting in inﬂammation and
ﬁbrosis are not completely understood. However, recent
understanding of the inﬂammasome pathway has lead to
recognition for the role of the inﬂammasome in PF devel-
opment and pathogenesis [49].
Some agents that have been associated with the develop-
ment of the nonidiopathic forms of PF, such as asbestos and
silica, have also been shown to induce lysosomal membrane
permeabilization and assembly of the inﬂammasome [56,
57]. Permeabilization of the lysosomal membrane results in
the release of proteases such as cathepsin B into the cytosol
[53, 54]. Cathepsin B activates the NALP3 inﬂammasome
and ultimately leads to IL-1β and IL-18 cleavage from
their proisoforms [52, 58]. In addition, evidence suggests
that maturation of IL-1β and IL-18 plays a critical role
in acute and chronic inﬂammation, similar to what is
observed in cases of PF [37]. For example, a role for IL-
1β in ﬁbrogenesis has been established using IL-1 receptor
deﬁcient mice, possibly through stimulation of the matrix
metalloproteinases [59]. In fact, gene expression analysis
of patients with histologically proven PF highlighted the
importance of matrix metalloproteinase 7, an observation
that was supported with studies using matrix metallopro-
teinase 7 knock-out mice [60]. Similarly, neutralization of
IL-18 has been shown to reduce obstruction-induced renal
ﬁbrosis [61] and is also known to induce gene expression
of IL-1 [44]. IL-1β, in particular, is an important mediator
of the inﬂammatory response following injury or infection
[62] and may be a therapeutic target for chronic lung
inﬂammation and ﬁbrosis [25].
Characteristicchangesinproinﬂammatorycytokinepro-
ﬁles associated with the inﬂammasome may also result in
the recruitment of ﬁbroblasts and inﬂammatory cells [63].
Fibroblasts and myoﬁbroblasts provide a structural platform
for the lung and may be key eﬀectors in PF development.
Activation of ﬁbroblasts and myoﬁbroblasts is a pathological
hallmark of PF and most likely results from the downstream
eﬀects of abnormal cytokine, chemokine, and growth factor
activity. In areas with increased ﬁbroblast activity, excessive
deposition of extracellular matrix along with loss of the
normal structural components of the lung is observed
[64].
3.3. Downstream Eﬀects of IL-1β and IL-18. The proin-
ﬂammatory cytokines of the IL-1 family, including IL-
1β and IL-18, play important roles in antimicrobial host
defense as well as the modulation of gene expression. Once
assembly of the inﬂammasome and subsequent activation
of the cytokines IL-1β a n dI L - 1 8h a so c c u r r e dv i ac l e a v a g e
of their proisoforms, a proinﬂammatory cascade of events
is likely to follow. In vivo, IL-1β is primarily responsible
for symptoms of acute inﬂammation such as fever, acute
protein synthesis, anorexia, and sleep disturbances [65]. In
contrast, IL-18 is largely involved in Th1 responses [44]. In
addition, IL-1β and IL-18 play a primary role in diseases
involving the innate and acquired immune systems such as
PF, autoimmunity, rheumatoid arthritis, cancer, metabolic
syndrome, and atherosclerosis [66].
In renal ﬁbrosis, activation of the inﬂammasome and
subsequent release of IL-1β, along with TNF-α and IFN-λ,
contributes to the epithelial mesenchymal transition [67], a
critical step in disease development that may have implica-
tions for PF. Furthermore, long-term exposure (>10 days) of
human epithelioid dermal microvascular endothelial cells to
IL-1β results in a permanent transformation into a myoﬁ-
broblast phenotype [68], possibly increasing susceptibility
for initiation of the ﬁbrotic process. Further increases in IL-
1β production will drive a subsequent increase in TGF-β,
resulting in increased collagen production by ﬁbroblasts—
also known to be a critical step in the development of
ﬁbrosis [69]. Thus, IL-1β and IL-18 most likely contribute to
favorable conditions for the development of ﬁbrotic lesions
such as increased collagen production and transformation of
nonﬁbroblastic cells into a phenotype more typically seen in
ﬁbroblasts or myoﬁbroblasts. It is clear that dysregulation of
pathways leading to inﬂammation and the subsequent devel-
opment of ﬁbrosis is closely linked to the proinﬂammatory
cytokines IL-1β and IL-18, which in turn are dependent on
formation of an inﬂammasome complex for activation.
4. Inﬂammasome Activation
4.1. Mineral Particles. Inhalation of mineral particles such as
asbestosorsilicainenvironmentaloroccupationalexposures
over an extended period of time can result in the non-
idiopathic form of PF. Recent studies have demonstrated
that silica internalization leads to lysosomal destabilization
and NALP3 inﬂammasome activation [52]. Furthermore,
Cassel and colleagues [57] have shown that the NALP3
inﬂammasome is essential for development of silicosis. In
addition, silica exposure activates caspase-1 leading to IL-1β
maturation and inﬂammation following lysosomal damage
[70].
Other mineral ﬁbers such as asbestos lead to an
irreversible ﬁbrotic condition known as asbestosis after
prolonged exposure. Recent studies have provided clues as
to the molecular mechanism by which asbestos leads to
pulmonary inﬂammation and ﬁbrosis. Similar to that seen
with silica, asbestos exposure results in activation of the
NALP3 inﬂammasome and IL-1β secretion by macrophages
[56].Pulmonary Medicine 5
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Figure 2: Potential inﬂammasome targets for novel PF therapeutics. Lysosomal membrane permeabilization plays an important role in
cathepsin B release and inﬂammasome activation. Therefore, stabilization of the lysosomal membrane would prevent initiation of the
adverse events associated with inﬂammasome activation. Similarly, inhibition of cathepsin B would attenuate inﬂammasome assembly
and activation. Further downstream of inﬂammasome assembly, inhibition of caspase -1, would prevent maturation of proinﬂammatory
cytokines such as IL-1β and IL-18. In addition, IL- 1R antagonists would prevent the downstream events following the binding of IL-1β to
its receptor.
4.2.Nanomaterials. Nanomaterialsareengineeredstructures
with at least one dimension of 100 nanometers or less and
signiﬁcant potential to be designed in a multitude of shapes
and sizes [71]. These materials are increasingly being used
for commercial purposes due to their exceptional proper-
ties of conductivity, reactivity, and optical sensitivity [71].
Furthermore, modiﬁcation of nanomaterials resulting in a
wire,ﬁber,belt,ortubeisanattractivemethodforenhancing
the end-product usage. However, toxicity and pathological
potential can change dramatically when the nanomaterial
shape is altered. In particular, if the nanomaterial becomes
diﬃcultforaphagocyticcelltoprocess,lysosomaldisruption
and NALP3 inﬂammasome activation may occur [72].
5. Current and Future Treatment
Options For PF
5.1. Current Treatment Options in Clinical Trial. Current
pharmacological treatment of PF is based on a combination
of corticosteroids and immunosuppressants. However, the
eﬃcacy of treatment remains a matter of debate and these
medications have serious adverse side eﬀects. It is beyond
the scope of this paper to include a discussion of all current
treatment regimens; however, there are several comprehen-
sivereviewsdiscussingtheoutcomesoftrialsaimedattesting
standard therapies for PF [73, 74].
5.2. New Pharmacological Agents. In recent years, there has
been an increase in the launch of new pharmacological
agents that are currently in clinical trial stage. Some of these
therapeutic agents are interferon gamma, N-acetylcysteine,
etanercept (antitumor necrosis factor α), bosentan (antien-
dothelin dual receptor antagonist), and imatinib (tyrosine
kinases inhibitor of the PDGF receptor) to name a few.
Agents involved in the inﬂammasome pathway are
currently being studied as potential therapeutics for PF as
well. For example, the successful use of the IL-1 receptor
antagonist, anakinra, to treat bleomycin-induced PF in mice
has raised the possibility for its use in human trials [36]. In
fact, anakinra is currently being used for the treatment of
otherinﬂammatorydiseasessuchasMuckle-WellsSyndrome
[75] and rheumatoid arthritis [76]. In addition, inhibition
of cathepsin B, an inﬂammasome activator, has signiﬁcant
potential for therapeutic application in diseases linked to
lysosomal dysfunction such as PF [54]. Speciﬁcally, Liu et
al. [77] reported a mechanism by which the transcription
factor NF-κB can inhibit inﬂammation, cell death, and6 Pulmonary Medicine
the subsequent formation of ﬁbrosis through its regulation
of the serine protease inhibitor 2A, a potent inhibitor of
cathepsin B [78]. Therefore, it is possible that drugs aimed
at other components involved in inﬂammasome activation
and activity could have potential to be highly eﬃcacious in
reversing or lessening the initial eﬀects associated with the
onset of PF (see Figure 2).
6. Conclusions
Pulmonary ﬁbrosis is a progressive, disabling, and fatal
disease. Present treatment options for PF are inadequate due
toanincompleteunderstandingofthemolecularmechanism
of the disease progression. Recent research focused on
understanding the molecular mechanism of PF development
has suggested that inﬂammasome activation may play a role
in initiation and/or progression of the disease. In addition,
inﬂammasome activation is involved in the development of
other inﬂammatory and ﬁbrotic diseases, which may provide
clues for our current understanding of PF. Speciﬁcally, the
NALP3 protein is most likely responsible for inﬂammasome
activation leading to proIL-1β and proIL-18 cleavage and
maturation by active caspase-1, which contributes to ﬁbrosis
development. In fact, evidence suggests that maturation of
IL-1β and IL-18 plays a critical role in acute and chronic
inﬂammation, similar to what is observed in cases of PF
[37], and may result in the recruitment of ﬁbroblasts
and inﬂammatory cells [63]. Fibroblasts and myoﬁbroblasts
provide a structural platform for the lung and may be
key eﬀectors in PF development. Activation of ﬁbroblasts
and myoﬁbroblasts is a pathological hallmark of PF and
most likely results from the downstream eﬀects of abnormal
cytokine, chemokine, and growth factor activity, such as
what is observed following inﬂammasome activation.
In addition to aberrant regulation of cytokines, the
adaptor protein ASC is an important component of the
inﬂammasome complex and is known to play a crucial role
in the development of bleomycin-induced PF [25]. There-
fore, identifying critical components of the inﬂammasome
complex and its downstream eﬀectors, such as NALP3,
ASC, IL-1β, and IL-18, may be key for developing potential
therapeutic targets, which will be important for novel PF
treatments in the future.
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